RP902 / Risen (Suzhou) Biosci - LARVOL DELTA

Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease (GlobeNewswire) - "The Phase 2 clinical trial is a multicenter, randomized, double-blind, placebo-controlled phase study to evaluate the safety and efficacy of RP902 in the treatment of mild cognitive impairment (MCI) due to Alzheimer’s Disease. The primary endpoint is the change from baseline in the Clinical Dementia Rating Scale–Sum of Boxes (CDR-SB) score."

Trial status • Alzheimer's Disease • Cognitive Disorders